Coping with PBC: treatment challenges and QoL insights

Drs Marlyn Mayo and Gideon Hirschfield discuss the unmet needs in PBC management, highlighting the significant burden that symptoms pose for patients, the importance of monitoring and a patient-centric management approach offering insights into what might lie ahead in 2024.

CME case study for the identification and management of Primary Biliary Cholangitis (PBC) including therapy response and disease management, for a 42 year old with abnormal liver blood test results.

This CME-accredited expert discussion aims to highlight the unmet needs in late-onset genetic cholestasis and provide guidance on the use of genetic testing in the diagnostic workup and initial management steps for the different genotypes, with reference to key trials and updates from The Liver Meeting 2024: American Association for the Study of Liver Diseases (AASLD).

Dr Andrew Stolz reports on the relationship between alterations to the ABCB11 gene and the risk of drug-induced liver injury from anabolic steroids.

Denosumab is comparable to bisphosphonates for treating osteoporosis in patients with primary biliary cholangitis, but with fewer adverse effects.

Led by Emma Culver, this interactive case study follows a 40-year-old woman who is referred to the clinic following profound fatigue, and discusses how management plans can be personalized to best support patient outcomes.

Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.

Dr Palak Trivedi joins Dr Gideon Hirschfield to explore pivotal insights from The Liver Meeting 2023. Together, they highlight crucial updates, unveil novel findings, and deliver a concise overview of the current landscape of PBC.